Theravance Biopharma, Inc.
NASDAQ:TBPH
9.86 (USD) • At close December 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Theravance Biopharma, Inc. |
Symbool | TBPH |
Munteenheid | USD |
Prijs | 9.86 |
Beurswaarde | 484,858,598 |
Dividendpercentage | 0% |
52-weken bereik | 7.44 - 11.71 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Rick E. Winningham M.B.A. |
Website | https://www.theravance.com |
An error occurred while fetching data.
Over Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK)
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)